Cholecalciferol

Intervention4 papers5 findingsPubChem 5280795ChEBI 28940MeSH D002762

Human trial4

Outcomes

NfL

downin humans1Moderate certainty

1 study

Cholecalciferol decreases NfL in humans (-16.2% (95% CI: -30.5% to 1.1%)).
Human trialin Black participantsplasma2000 IU/day4 years
Effects of long-term daily supplementation with vitamin D3 and marine omega-3 fatty acids on change in ADRD biomarkers: A secondary analysis of a randomized clinical trial · Alzheimer's & dementia (New York, N. Y.) · 14 Sep 2026

NfL →

Plasma ADRD biomarkers

no changein humans1Moderate certainty

1 study

Cholecalciferol has no effect on plasma ADRD biomarkers in humans.
Human trialover 4 yearsplasma2000 IU/day4 yearsn = 929
Effects of long-term daily supplementation with vitamin D3 and marine omega-3 fatty acids on change in ADRD biomarkers: A secondary analysis of a randomized clinical trial · Alzheimer's & dementia (New York, N. Y.) · 14 Sep 2026

Plasma ADRD biomarkers →

25-hydroxyvitamin D

upin humans1Moderate certainty

1 study

Cholecalciferol increases 25-hydroxyvitamin D in humans (73.0 vs 99.7 vs 120.4 nmol/L).
Human trial12 monthsn = 550
The effect of vitamin D₃ supplementation on fracture incidence in an aging population - The Finnish vitamin D trial · Bone · 7 Sep 2026

25-hydroxyvitamin D →

Fracture risk

no changein humans1HR 1.07Moderate certainty

1 study

Cholecalciferol has no effect on fracture risk in humans (HR 1.07, 95% CI 0.72-1.58).
Human trialcompared to placebo3200 IU/daymean 4.1-year
The effect of vitamin D₃ supplementation on fracture incidence in an aging population - The Finnish vitamin D trial · Bone · 7 Sep 2026

Associations

Fracture risk

upin humans1HR 1.52Moderate certainty

1 study

Cholecalciferol raises the risk of fracture risk in humans (HR 1.52, 95% CI 1.06-2.18).
Human trialcompared to placebo1600 IU/daymean 4.1-year
The effect of vitamin D₃ supplementation on fracture incidence in an aging population - The Finnish vitamin D trial · Bone · 7 Sep 2026

Trials

352

In trials

Vitamin D deficiency
Phase 4 · Results posted · 88 trials
Osteoporosis
Phase 4 · Completed · 27 trials
Diabetes mellitus
Phase 4 · Completed · 17 trials
Insulin resistance
Phase 4 · Results posted · 15 trials
COVID-19
Phase 4 · Completed · 12 trials
Obesity
Phase 4 · Results posted · 12 trials

40 of 151

Metabolic bone disease
Phase 4 · Results posted · 11 trials
Type 2 diabetes
Phase 4 · Completed · 11 trials
Asthma
Phase 4 · Terminated · 8 trials
Crohn's disease
Phase 4 · Completed · 8 trials
Type 1 diabetes
Phase 4 · Completed · 8 trials
Chronic Renal Insufficiency
Phase 4 · Completed · 7 trials
Multiple sclerosis
Phase 4 · Terminated · 6 trials
Neoplasm
Phase 4 · Completed · 6 trials
Critical illness
Phase 4 · Completed · 5 trials
Inflammatory bowel disease
Phase 4 · Completed · 5 trials
Myelodysplastic syndrome
Phase 4 · Completed · 5 trials
Cardiovascular disease
Phase 4 · Terminated · 4 trials
Depression
Phase 4 · Terminated · 4 trials
Postmenopausal osteoporosis
Phase 4 · Results posted · 4 trials
Breast Feeding
Phase 4 · Completed · 3 trials
Coronavirus Infections
Phase 4 · Completed · 3 trials
Cystic Fibrosis
Phase 4 · Completed · 3 trials
Glucose Intolerance
Phase 4 · Completed · 3 trials
Hyperparathyroidism
Phase 4 · Completed · 3 trials
Non-alcoholic fatty liver disease
Phase 4 · Completed · 3 trials
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Phase 4 · Completed · 3 trials
Ulcerative Colitis
Phase 4 · Completed · 3 trials
Vascular calcification
Phase 4 · Status unknown · 3 trials
Autoimmune disease
Phase 4 · Completed · 2 trials
Chronic Kidney Failure
Phase 4 · Completed · 2 trials
Epilepsy
Phase 4 · Completed · 2 trials
Iron deficiency
Phase 4 · Completed · 2 trials
Motor Activity
Phase 4 · Completed · 2 trials
Osteoarthritis
Phase 4 · Active, not recruiting · 2 trials
Pain
Phase 4 · Completed · 2 trials
Parkinson's disease
Phase 4 · Terminated · 2 trials
Pediatric obesity
Phase 4 · Status unknown · 2 trials
Pneumonia
Phase 4 · Completed · 2 trials
Pre-eclampsia
Phase 4 · Completed · 2 trials

Readouts due

Jul 2027
The Prospective Improved Vitamin D Study for Inflammatory Bowel Disease Patients
Phase 1 · Active, not recruiting

Stopped

NCT01817699 · Terminated · Vitamin D deficiency
The independent Data Monitoring Committee recommended an early termination.
NCT02208310 · Terminated · Vitamin D deficiency
Unable to enroll at rate anticipated, insufft low vitamin D in clin rem @ 5 sites
NCT03380091 · Terminated · Vitamin D deficiency
Recruitment challenges
NCT04629534 · Terminated · Vitamin D deficiency
low enrollment, lack of funding
NCT02424552 · Terminated · Asthma
recruitment problems
NCT01005095 · Terminated · Multiple sclerosis
Interim analysis showed that the odds for proving primary hypothesis are low.

All 18

NCT00058188 · Terminated · Prostatic Neoplasms
Closed by the research committee
NCT05018585 · Terminated · Immune system disease
Stopped for futility.
NCT01264874 · Terminated · Melanoma
poor accrual rate
NCT01809171 · Terminated · Musculoskeletal disease
Inclusion problems
NCT01198548 · Terminated · Colonic Neoplasms
Lack of funding
NCT00104806 · Terminated · Leukemia
sponsor discontinues support
NCT01521936 · Terminated · Leukemia, Myeloid, Acute
Lack of funding
NCT02341495 · Terminated · Leukemia, Myeloid, Acute
Study was terminated early due to low patient accrual.
NCT03313076 · Terminated · Burns
COVID-19 global pandemic, and study funding period ended 7/31/2020.
NCT02877641 · Terminated · Muscle weakness
low accrual
NCT03302585 · Terminated · Optic neuritis
inability to meet recruitment goals
NCT02387164 · Terminated · Prediabetic state
The study was interrupted early and terminated when only 26 out of 80 patients were enrolled due to new clinical study results indicating that the current study would not be informative.